期刊文献+

高效液相色谱法测定非诺贝酸的含量和有关物质

Determination of Fenofibric Acid and its Related Substances by HPLC
原文传递
导出
摘要 建立同时测定非诺贝酸含量和有关物质的高效液相色谱法。采用苯基硅烷键合硅胶柱(4.6 mm×250 mm,5μm),流动相为10 mmol/L磷酸二氢钾溶液(用磷酸调节p H值至2.5)-乙腈(35∶65),体积流量为1.0 m L/min,检测波长为287 nm,柱温为室温。应用该色谱条件进行有关物质测定时,非诺贝酸与各有关物质之间分离度良好,各杂质对主成份的含量测定无影响。非诺贝酸浓度在0.100 2~1.002μg/m L范围内与峰面积呈现良好的线性关系,r=0.999 9,平均回收率为99.60%,99.81%,99.85%,RSD值为0.8%。定量限为50.25 ng。最低检出限为12.65 ng。3批样品的含量测定结果分别为99.10%,99.58%,100.02%。总杂质分别为:0.05%,0.07%,0.07%。该方法灵敏度高,简单易行,结果准确可靠,可用于测定非诺贝酸的含量和有关物质。 To establish a HPLC method for detemination of fenofibric acid and its related substances.A phenyl column(4.6 mm ×250 mm,5 μm) was used,the mobile phase for the content determination was acetonitrile-10 mmol / L potassium dihydrogen phosphate solution(65∶ 35,adjusted to p H 2.5 with phosphoric acid) at the detection wave length of 287 nm and the column temperature of room temperature.The results showed that fenofibric acid and its related substances were separated quite well under the above conditions.Excipients showed no interference with determination of the main component.Fenofibric acid concentration was within0.100 2 ~ 1.002 μg / m L range and the peak area exhibited a good linear relationship,and the correlation coefficient was 0.999 9,the average recovery was 99.60%,99.81%,99.85%,with RSD of 0.80%.The limit of detection was 50.25 ng,and the minimum detection limit of 12.65 ng.Determination results of three batches of samples were 99.10%,99.58%,100.02%,respectively.The total impurities were 0.05%,0.07% and 0.07%,respectively.The method is sensitive,simple,accurate and reliable for the determination of fenofibric acid and related substances.
出处 《药物生物技术》 CAS 2016年第5期403-406,共4页 Pharmaceutical Biotechnology
关键词 非诺贝酸 非诺贝酸含量 非诺贝酸有关物质 高效液相色谱 含量 有关物质 Fenofibric Acid Content of fenofibric acid Related substances of Fenofibric acid HPLC Content Related Substances
  • 相关文献

参考文献5

二级参考文献21

  • 1商希礼,徐俊英,孙日圣,虞华,邱宝玉.青霉素亚砜扩环制头孢菌素中间体的研究[J].江西化工,2004,20(4):97-101. 被引量:2
  • 2高志伟,李中东,焦正,施孝金,钟明康.人血浆中非诺贝酸的的HPLC测定及药物动力学研究[J].中国医药工业杂志,2006,37(1):32-34. 被引量:6
  • 3赵永红,黄毅慧,黄仲义.非诺贝特胶囊(微粒化)人体生物利用度研究[J].中国药房,2006,17(14):1082-1083. 被引量:11
  • 4徐帆,冯恩富,余昉.HPLC法测定血浆中非诺贝特活性代谢物非诺贝酸的浓度[J].中国药师,2007,10(6):530-532. 被引量:9
  • 5张玉奎,王杰,张维冰,等译.实用高效液相色谱法的建立[M].北京:科学出版社,1998:98-104.
  • 6Campbell J,Mohiuddin SM.The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2diabetes[J].Drugs Today,2010,46(10):757-764.
  • 7Masnatta LD, Caniberti LA, Rey RH. Determination of bezafibrate ciprofibrate and fenofibric acid in human plasma by HPLC[J ] .J Chromagra B Biomed Appl , 1996, 687(4) : 437.
  • 8Streel B, Hubeert Ph, Ceccato A. Determination of fenofibric acid in human plasma using automated solid-phase extraction coupled to liquid chromatography [J ] .J Chromagra B Biomed Sci , 2000,742(6) : 391.
  • 9Hinz A, Gordon KC, Goverin CM, et al. Understanding the solid- state forms of fenofibrate -A spectroscopic and computational study [J]. Eur J Pharm Biopharm,2009,71 ( 1 ) :100-108.
  • 10Godfrey AR, Digiacinto J, Davis MW. Single-dose bioequivalence of 105-mg fenofibr~c acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, sin- gle-dose, randomized, crossover clinical trials[ J]. Clin Ther, 2011, 33(6) :766-775.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部